← BackCOLLEGIUM PHARMACEUTICAL, INC · DrugmakersCOLL
Low riskNext report: Around Nov 5 (est.)
The short versionA profitable company with steady sales. Institutions are adding.
Going well
- Profitable
- Sales up 24% last year
- Brings in more cash than it spends
Watch out for
- Share count growing 5.5% a year
Money moves
- No insider buying or selling in the last 30 days
- Institutions added 3.8% to their holdings in the quarter ending June 2026 (162 bought, 113 sold)
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$23.23+1.2% that day
- Company value
- $756M
- Share price times all shares
- Price vs profit (P/E)
- 18.7x
- You pay about $19 for each $1 of yearly profit
- Price vs sales
- 0.94x
- Company value is 0.94 times a year of sales
- Cash vs value
- 17%
- Cash as a share of company value
- Debt vs value
- 72%
- Debt as a share of company value
From COLL's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
The business over time
Last 12 quarters, from SEC filings
Sales, Jun '26$199.9M+6.3% vs a year earlier
Sep '23Tap a barJun '26
Last 12 months: $808.2M, up 14% from the 12 months before. Over 5 years, sales grew about 20% a year.
Business quality
The checklist Warren Buffett-style investors use. Annual numbers for 2025.- PassReturn on equity 15%+Earns a lot on the money owners have in the business.23.8%
- MissDebt under half of equityNot relying on borrowed money.1.80x equity
- MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.8.1%
- MissProfitable every yearSteady profits, not one good year.5 of 10 years
- PassFree cash flow positiveBrings in more cash than it spends to run and grow.$327.6M
- MissShare count not growingNot diluting owners. Falling means buybacks.+17.4% in 3 years
- PassGross margin 40%+Pricing power: sells for well above what it costs to make.59.3%
- Revenue
- $780.6M
- +23.6% vs prior year
- 5-year growth
- +20.3%/yr
- revenue, per year
- Total debt
- $542.1M
- 1.80x equity
- Current ratio
- 1.57x
- short-term assets / bills due
From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Jun 30, 2026- Revenue
- $199.9M
- +6.3% YoY
- EPS
- -$0.46
- vs $0.34
- Op. margin
- 1.9%
- -16.8 pts
- Gross margin
- 55.2%
- -2.5 pts
- Free cash flow
- $70.8M
- Share count
- -16.9%
- vs a year ago
Insider rating
Last 90 days
No open-market insider buys or sells in the last 90 days.
Weekly insider trendNo trades to chart yet.
Filing buzz
Last 7 days vs normal
0/ 100
- This week
- 0
- Normal week
- 0.8
- vs normal
- 0.0x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
▲Accumulating+3.8%Institutions added 3.8% to their holdings. 162 bought, 113 sold.
Shares held by institutions39.5M
Sep '24Jun '26
Share count growthYearly rate, last 3 years
-2.1%Cash runwayAt last year's cash burn
Cash flow positiveDebt to equityLatest balance sheet: debt compared with what owners have
2.6x · $797.8M debtShares outstandingLatest reported
33MNext reportAround Nov 5 (est.)Estimated from the same quarter last year
- Results filedAug 6
- Results filedMay 7
- Results filedFeb 26
- Results filedNov 6, 2025
- Results filedAug 7, 2025
Insider trades
Open-market buys and sells, last 90 days
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.